Results from the ASSURE clinical trial have recently been published in the Lancet. ASSURE compared the effect of adjuvant sorafenib or sunitinib with placebo in renal cell carcinoma (RCC) patients who had had their tumours surgically removed, and who had a high risk for recurrence. The trial was conducted in the US and Canada, and initial results were published towards the end of last year (2015).
Treatment with sorafenib or sunitinib after surgery to remove local kidney cancer (no spread/metastases) in patients at high risk for recurrence did not increase survival in this double-blind, placebo-controlled phase III trial. Moreover, treatment with sorafenib or sunitinib resulted in substantial toxicity, which led to discontinuation of the treatment, despite reductions in drug dose.